In this case report, we discuss the potential diagnostic difficulty of identifying the cause or origin of a cervical swelling, a clinical situation often encountered in otolaryn gol ogy patients. A 30-year-old man came to us with a painless left cervical lump that he had noticed 8 weeks earlier. A series of examinations-including various biopsies, computed tomography, and extensive staging procedures-could not establish the diagnosis. We eventually identified the mass as an extragonadal germ-cell tumor. The diagnosis was established only aft er additional serologic testing and detection of tumor markers specific for extragonadal germ-cell tumor.
Introduction
The diagno sis and treatment of a cer vical lump is a routin e clinical undertaking for the ENT surgeon. The comm on differenti al diagnoses include metastases of malignancies primary to the head and neck, malignant lymphoma, and cancer of unknown primary site (CUP). Less common possibilities are manifestation s of cancers primary to the stomach, breast, or }ung. In this article, we describe the case of a patient with a cervical lump that was diagnosed as an extragonadal germ-cell tumor only after extensive investigation. fied a palpable left supraclavicular mass appro ximatel y 5 em in diameter. There were no signs of infection. Findin gs on the remainder of the physical examin ation, includin g the patient ' s ENT status, were normal. Ultrasonography and computed tomography (CT) of the neck confirmed the presence of an inhomogeneous tumor that measured 37 x 58 x 69 mm (figure I). Panendoscopic findings in the upper respiratory tract and esophagus were normal. A representative biopsy was taken from the mass, which was initially thought to be a malign ant lymph oma. Histologic examination revealed the presence of a solid carcinoma. Immunohistochemical staining raised the possibility that the mass was a sinonasal carcinoma.
Case report
Further examination-including multiple nasopharyngeal biopsies and CT of the paran asal sinuses-failed to identify a carcinoma in this region . Likewise, thoracic and abdominal CT, gastroscopy, and positron -emis sion tomography (PET) all failed to provide information about the primary tumor (figure 2). The results of the urologi c examin ation were normal. Additional serologic testing revealed that the patient' s alpha-fetoprotein (AFP), human placent al alkaline phosphatase, prostate-specific antigen, carcinoembryonic antigen (CEA), carboh ydrate antigen 19-9 (CA 19-9), and thyroglobulin levels were within normal limit s. However, three other levels were slightly elevated: aspartate aminotransferase: 19UIL (normal: 3 to 18); alanine amin otransferase: 25 UIL (normal: 3 to 22); and lactate dehydrogenase: 264 UIL (normal: 40 to 240) , More over, other levels were significa ntly elevated: human chorionic gonadotropin beta (hCGB): 5,344 U/L (normal: <3); testosterone: 11.8 /lg/L (normal: 2,8 to 8.0); and free testosterone: 44 .2 ng/L (normal: 18 to 41); these values suggested a diagnosis of a malignant extragonadal germ-cell tumor.
Examination of the histologic spec imen and immunohistochemical staining for hCGB confirmed that the mass was a nonseminomatous carcinoma. Becau se a complete restaging did not uncover a different primary tumor or a further metastasis, the diagnosis of nonseminomatous carcinoma primary to the supraclavicular lymph node was established.
The pat ient was started on cisplatin, etoposide, bleomycin, and paclitaxel. Completion of four courses of chemotherapy led to a significant regression of the tumor (as seen on CT and PET imaging) and a normal hCGI3 level. The residual mass was resected; histologic examination identified necrotic tissue , but no viable tumor cells.
Discussion
In a patient with a cervical lump, diagnostic procedures such as panendoscopy, biopsy, and staging will often, but not always , identify the site of the primary tumor. When the primary site is not identified, the surgeon must undertake further staging. A metastasis that appears as a solid carcinoma on histologic analysis in a patient in whom the origin of the primary tumor is unidentified is usually classified as a CUP .
The routine treatment of CUP syndrome is surgical resection and radiation. But as demonstrated in this case, serologic testing of tumor markers followed by immunohistologic re-examination might in fact lead to a diagnosis that requires an entirely different therapeutic strategy. Extragonadal germ-cell tumors are very rare , accounting for as few as 2 to 5% of all germ-cell neoplasms.' When they do occur, they usually do so in young men . The usual sites are the retroperitoneum and the mediastinum; occasionally they occur at more distant sites, such as the pineal gland, bladder, and stomach.
Primary extragonadal disease can occur in the absence of an occult neoplasm of the testes .' Like gonadal neoplasms, extragonadal germ-cell tumors are classified as 582 RUF .· Figure 2 . Prior to the induction ofchemotherapy, PET imaging did not detect furth er pathologicfindin gs apart from the supraclavicular mass.
either seminomatous or nonseminomatous. The latter is usually characterized by elevated levels of serum tumor markers, the most important being the AFP and hCGI3 levels . In our patient, the high hCGl3level was diagnostic; on the other hand, his AFP level, which is elevated in approximately 80% of patients with an extragonadal germ-cell tumor, was within normal limits . When both AFP and hCGI3 levels are normal in a patient with an extragonadal germ-cell tumor, measurement ofCEA and CA 19-9 levels prior to the induction of chemotherapy has been shown to be useful. '
There is no gold-standard treatment for extragonadal germ-cell carcinoma.' Intensive cisplatin-based chemotherapy followed by surgical removal of residual disease has been reported to result in an overall survival rate of 63 % at 6.8 years .' Elevated levels of the tumor markers AFP, hCGI3, CEA , and CA 19-9 are apparently a negative indicator for survival.' Even so, the utility of various outcome predictors remains controversial.
